scholarly journals Improvement of Cognitive Function after Computer-Based Cognitive Training in Early Stage of Alzheimer's Dementia

2017 ◽  
Vol 16 (1) ◽  
pp. 7 ◽  
Author(s):  
YoungSoon Yang ◽  
Yong Tae Kwak
2019 ◽  
Vol 18 (2) ◽  
pp. 62 ◽  
Author(s):  
Min Ju Kang ◽  
So Min Kim ◽  
Seo Eun Han ◽  
Ji Hyun Bae ◽  
Woo Jin Yu ◽  
...  

2016 ◽  
Vol 1 (2) ◽  
pp. 47-61 ◽  
Author(s):  
Kimberly D. Mueller

Computer-based cognitive training programs are increasing in popularity, not only due to trends in technological advances, but also due to the intense marketing campaigns of such programs toward late-middle-aged and older adults. This article's objective is to evaluate the effectiveness of computer-based cognitive training programs in maintaining or improving cognitive function in people with mild cognitive impairment (MCI) and early-stage Alzheimer's disease (AD). Twelve databases were searched using terms related to computerized cognitive training (CCT) and MCI and Alzheimer's disease (AD). Two raters independently extracted articles using agreed-upon criteria. Due to the heterogeneity of the samples, interventions, and outcomes, data of the studies was not statistically pooled for meta-analysis. Ten studies met the inclusion criteria and the findings were summarized. All of the studies reviewed provided support that computerized cognitive interventions are feasible in people with MCI or early-stage AD. None of the studies yielded significant evidence to support the use of CCT alone for improvement or maintenance of cognitive function in people with MCI or AD. Further, no studies presented significant evidence of transfer of training to everyday skills and tasks. Recommendations for evaluating products and for areas of research need are provided.


2011 ◽  
Vol 2011 ◽  
pp. 1-2 ◽  
Author(s):  
T. Grieco ◽  
M. Rossi ◽  
V. Faina ◽  
I. De Marco ◽  
P. Pigatto ◽  
...  

Rivastigmine is a cholinesterase inhibitor which improves cognitive function and is currently being used in patients with mild to moderate Parkinson's and Alzheimer's dementia. This drug can be given orally or topically, as transdermal patch. The latter form is currently used for most excellent compliance and few side effects. The most common cutaneous side effects are irritative dermatitis. We report the second case of active sensitization by the rivastigmine-patch in a patient suffering from Alzheimer's dementia.


2003 ◽  
Vol 13 ◽  
pp. S315
Author(s):  
W. Deberdt ◽  
P.P. De Deyn ◽  
M.M. Carrasco ◽  
C. Jeandel ◽  
D.P. Hay ◽  
...  

2021 ◽  
Vol 18 ◽  
Author(s):  
Yue Liu ◽  
Daniel Chan ◽  
John D Crawford ◽  
Perminder S Sachdev ◽  
Nady Braidy

Background: The interaction between cerebral vessel disease (CVD) pathology and Alzheimer’s disease (AD) pathology in the development of dementia is controversial. We examined the association of cerebral vascular neuropathology and cerebrovascular risk factors with the mild stage of Alzheimer's dementia and cognitive function. Methods: This cross-sectional study included men and women aged 60 years or over who had yearly clinical assessments and had agreed to brain autopsy at the time of death, and who contributed to data stored at the National Alzheimer's Coordinating Center (NACC) in the USA. Cognitively normal and impaired subjects with presumptive aetiology of AD, including mild cognitive impairment (ADMCI) and dementia (Alzheimer’s dementia), and with complete neuropathological data, were included in our analyses. We used neuropsychological data proximate to death to create summary measures of global cognition and cognitive domains. Systematic neuropathological assessments documenting the severity of cerebral vascular pathology were included. Logistic and linear regression analyses corrected for age at death, sex and Lewy body pathology were used to examine associations of vessel disease with the severity of Alzheimer's disease dementia, and cognitive function, respectively. Results: No significant relationship was observed between late-life risk factors and Alzheimer’s dementia. The severity of arteriosclerosis and presence of global infarcts/lacunes were related to mild Alzheimer’s dementia (B=0.423, p<0.001;B=0.366, p=0.026), and the effects were significant after adjusting for neuritic plaques and neurofibrillary tangles (B=0.385, p<0.001;B=0.63, p=0.001). When vascular brain injuries were subdivided into old and acute/subacute types, we found that old microinfarcts and old microbleeds were associated with mild Alzheimer’s dementia (B=0.754, p=0.007; B=2.331, p=0.032). The old microinfarcts remained significantly associated with mild Alzheimer’s dementia after correcting AD pathologies (B=1.31, p<0.001). In addition, the number of microinfarcts in the cerebral cortex had a significant relation with mild Alzheimer’s dementia, whether or not the data were corrected for AD pathologies (B=0.616, p=0.016; B=0.884, p=0.005). Atherosclerosis, arteriosclerosis and white matter rarefaction were found to be significantly associated with faster progression of Alzheimer’s dementia (B=0.068, p=0.001; B=0.046, p=0.016, B=0.081, p=0.037), but white matter rarefaction no longer had a significant effect after adjusting for AD pathologies. We also found that the severity of atherosclerosis was related to impairment in processing speed (β=-0.112, p=0.006) and executive function (β=-0.092, p=0.023). Arteriosclerosis was significantly associated with language (β=-0.103, p=0.011) and global cognition (β=-0.098, p=0.016) deficits. Conclusion: Our study found the significant relation of global, old, acute/subacute and regional cerebral vascular pathologies, but not white matter rarefaction, to the onset and severity of Alzheimer’s dementia. We also showed that late-life risk factors were found to have no relation with Alzheimer’s dementia, and the increased risk of dementia with APOE ε4 is not mediated by CVD. The best interpretation of these findings is that CVD has an additive effect with AD pathologies in the development and progression of what is clinically diagnosed as Alzheimer’s dementia, and it is very likely that CVD and AD are to a major degree independent pathologies.


2017 ◽  
Vol 29 (9) ◽  
pp. 1473-1482 ◽  
Author(s):  
Nahid Zokaei ◽  
Christopher MacKellar ◽  
Giedrė Čepukaitytė ◽  
Eva Zita Patai ◽  
Anna Christina Nobre

Development of measures to preserve cognitive function or even reverse cognitive decline in the ever-growing elderly population is the focus of many research and commercial efforts. One such measure gaining in popularity is the development of computer-based interventions that “exercise” cognitive functions. Computer-based cognitive training has the potential to be specific and flexible, accommodates feedback, and is highly accessible. As in most budding fields, there are still considerable inconsistencies across methodologies and results, as well as a lack of consensus on a comprehensive assessment protocol. We propose that the success of training-based therapeutics will rely on targeting specific cognitive functions, informed by comprehensive and sensitive batteries that can provide a “fingerprint” of an individual's abilities. Instead of expecting a panacea from training regimens, focused and personalized training interventions that accommodate individual differences should be developed to redress specific patterns of deficits in cognitive rehabilitation, both in healthy aging and in disease.


2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Sonal Agrawal ◽  
Lei Yu ◽  
Sukriti Nag ◽  
Konstantinos Arfanakis ◽  
Lisa L. Barnes ◽  
...  

AbstractLewy bodies (LBs) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) are common in older persons and associated with cognitive impairment. However, little is known about the relationship between LBs and LATE-NC and their combined roles in cognitive impairment and Alzheimer’s dementia in community-dwelling participants. The study included 1670 community-based participants (mean age-at-death, 89.5 years (SD = 6.65); 69% females) who underwent annual assessments of cognition to create summary measures of global cognition and cognitive domains and evaluation for Alzheimer’s dementia. Systematic neuropathologic evaluations were performed to assess LBs, LATE-NC, and Alzheimer’s disease (AD) pathology. We excluded cases with pathologically confirmed frontotemporal lobar degeneration in this study. Logistic and linear regression analyses were used, adjusted for demographics and AD pathology. LBs were present in 428 (25.6%) decedents (29 nigra-predominant, 165 limbic-type, and 234 neocortical-type) while 865 (51.7%) decedents exhibited LATE-NC (307 stage 1, 167 stage 2, and 391 stage 3). LBs combined with LATE-NC were common (15% of all participants) and in those with Alzheimer’s dementia (25%). Neocortical-type, but not nigral-predominant or limbic-type LBs increased the odds of stage 2/3 LATE-NC (odds ratio = 1.70; 95% confidence interval = 1.26–2.30). The association between neocortical-type LBs and stage 2/3 LATE-NC was stronger in those under 90 years of age and in women. In analyses of cognition and Alzheimer’s dementia, LATE-NC and neocortical-type LBs, separately, were related to lower global cognition, five specific cognitive domains, and an increased odds of Alzheimer’s dementia, above and beyond the AD pathology. Limbic-type LBs were related to lower global cognition, and the domains of episodic, working, and semantic memory, and increased odds of Alzheimer’s dementia. Furthermore, there was no interaction between limbic/neocortical-type LBs and LATE-NC on cognitive function, cognitive domains, or Alzheimer’s dementia. These findings suggest that neocortical-type LBs are associated with LATE-NC, specifically in the younger old and in women. Limbic/neocortical-type LBs and LATE-NC have separate and additive effects on cognitive function and odds of Alzheimer’s dementia.


Sign in / Sign up

Export Citation Format

Share Document